Bosentan
Pulmonary Arterial Hypertension
Rajan SaggarSmall moleculePhase 4 / ApprovedDormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Pulmonary Arterial Hypertension cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zamicastat Bial - Portela C S.A. | Phase 2 | B |
Sildenafil University of California, Los Angeles | Phase 4 | B |
BARDOXOLONE METHYL ESTER Biogen | Phase 2 | B |
TREPROSTINIL PHOSPHATE Rajan Saggar | Phase 2 | B |
Same molecule, other indications
Bosentan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →